

[TO BE PUBLISHED IN THE GAZETTE OF INDIA, EXTRAORDINARY, PART II, SECTION 3, SUB-SECTION (i)]

GOVERNMENT OF INDIA
MINISTRY OF FINANCE
(DEPARTMENT OF REVENUE)

Notification No. 83 /2017-Customs

New Delhi, the 31st October, 2017

G.S.R. (E). - In exercise of the powers conferred by sub-section (1) of section 25 of the Customs Act, 1962 (52 of 1962), the Central Government, on being satisfied that it is necessary in the public interest so to do, hereby makes the following further amendments in the notification of the Government of India, in the Ministry of Finance (Department of Revenue), No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), *vide* number G.S.R.394 (E), dated the 20th April, 2017, namely: -

In the said notification, in the Table, after serial number 27 and the entries relating thereto, the following serial numbers and entries shall be added, namely: -

(1)	(2)	(3)	(4)
“28.	Erlotinib (Tarceva)	The Blue Tree	Roche Products (India) Private Limited
29	Trastuzumab (Herclon)	The Blue Tree	Roche Products (India) Private Limited
30.	Pertuzumab (Perjeta)	The Blue Tree	Roche Products (India) Private Limited
31.	Transtuzumab Emtansine (Kadcyla)	The Blue Tree	Roche Products (India) Private Limited
32.	Obinutuzumab (Gazyva)	The Blue Tree	Roche Products (India) Private Limited
33.	Bevacizumab (Avastin)	The Blue Tree	Roche Products (India) Private Limited
34.	Tocilizumab (Actemra)	Care for Joints	Roche Products (India) Private Limited
35.	Mycophenolate Mofetil (CellCept)	Aarambh	Roche Products (India) Private Limited
36.	Avonex (Interferon Beta 1A)	Reach	UCB India Private Limited
37.	Tysabri (Monoclonal Antibody)	Reach	UCB India Private Limited
38.	Tecfidera (Di- methyl Fumarate)	Reach	UCB India Private Limited
39.	Plegridy	Reach	UCB India Private Limited

	(Peggylated Interferon Beta 1A)		
40.	Sorafenib (Nexavar)	NexCSP (Nexavar Cancer Survivorship Program)	Bayer Zydus Pharma Private Limited
41.	Sirturo (Bedaquiline)	Bedaquiline Compassionate Use Program	Janssen India, Johnson & Johnson Private Limited
42.	Darzalex (Daratumumab)	Daratumumab Patient Assistance Program	Janssen India, Johnson & Johnson Private Limited
43.	SUTENT	- Patients initially pay for 12 strips (value equivalent of 50 mg) and gets assistance of 12 strips free. - Post purchase of 12 strips patients receive the drug free until prescribed by treating physicians. -Full subsidy for BPL patients	Pfizer Products India Private Limited
44.	CRIZALK	Patients will pay for 8 bottles (either 200 mg or 250 mg) and post that will get the drug free until prescribed by treating physician. - Full subsidy for BPL patients	Pfizer Products India Private Limited
45.	INLYTA	Sutent Patients who progresses and prescribed Inlyta as 2nd line pays for 1 strip and gets 1 strip free. - Patients who progresses on other 1st line TKI pays for 2 strips and get 1 strip free. -Full subsidy for BPL patients	Pfizer Products India Private Limited
46.	PALBACE	-Patients will pay for 10 cycles and post that will get free drug support until prescribed by treating physicians. - Full subsidy for BPL patients	Pfizer Products India Private Limited
47.	ENBREL	ENLIVEN -Enbrel 50 mg: 4+2PAP. Any further repeat purchase will be given at a further discounted price	Pfizer Limited

		-Enbrel25mg: 8+4 PAP. Any further repeat purchase will be given at a further discounted price	
48.	XELJANZ	XELSOURCE India specific price of Rs. 24000 per bottle (MRP is Rs. 66000 per bottle)	Pfizer Limited
49.	GENPTROPIN	5+1 PAP	Pfizer Products India Private Limited
50.	Atgam	For AIIMS Delhi 5+1, KEM Mumbai 4+1, CMC Vellore 4+1 & Other hospitals 20+4	Pfizer Products India Private Limited
51.	Aromasin	PAP 1+1	Pfizer Products India Private Limited
52.	Campto	PAP 1+1	Pfizer Products India Private Limited”.

[F. No. 332/24/2010-TRU (Pt. I)]

(Ruchi Bisht)

Under Secretary to the Government of India

Note: The principal notification No. 16/2017-Customs, dated the 20th April, 2017, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) *vide* number G.S.R.394 (E), dated the 20th April, 2017.